TRPV1 and SP: Key elements for sepsis outcome?

British Journal of Pharmacology

Volumn 170, Issue 7, 2013, Pages 1279-1292

  Bodkin, Jennifer Victoria ^a   Fernandes, Elizabeth Soares ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b CEUMA UNIVERSITY   (Brazil)

Author keywords

sensory neurones; sepsis; substance P; TRPV1

Indexed keywords

ANANDAMIDE; BRADYKININ; C REACTIVE PROTEIN; CAPSAZEPINE; COMPLEMENT RECEPTOR; CREATININE; GAMMA INTERFERON; GLUCOSE; HYDROGEN PEROXIDE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; NEUROKININ 1 RECEPTOR; NEUROKININ A; NEUROKININ B; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y; PREPROTACHYKININ; PROCALCITONIN; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR; RANTES; SUBSTANCE P; TACHYKININ; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VANILLOID RECEPTOR 1; AUTACOID; NEUROKININ 1 RECEPTOR ANTAGONIST; TRPV1 PROTEIN, HUMAN; VANILLOID RECEPTOR;

AMINO ACID SEQUENCE; ARTHRITIS; BACTERIAL GROWTH; BACTERIAL TRANSLOCATION; CALCIUM MOBILIZATION; CARBOXY TERMINAL SEQUENCE; CYSTITIS; DISEASE COURSE; EDEMA; ENTERITIS; ENZYME ACTIVATION; ENZYME ACTIVITY; FEVER; GENE; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PANCREATITIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SENSORY NERVE CELL; SEPSIS; SHOCK; TAC1 GENE; TAC2 GENE; TAC3 GENE; TACHYCARDIA; VASODILATATION; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; INFLAMMATION MEDIATORS; NEUROKININ-1 RECEPTOR ANTAGONISTS; RECEPTORS, NEUROKININ-1; SENSORY RECEPTOR CELLS; SEPSIS; SIGNAL TRANSDUCTION; SUBSTANCE P; TRPV CATION CHANNELS;

EID: 84887716318     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12056     Document Type: Review

References (174)

1. Ahluwalia A, De Felipe C, O'Brien J, Hunt SP, Perretti M, (1998). Impaired IL-1beta-induced neutrophil accumulation in tachykinin NK1 receptor knockout mice. Br J Pharmacol 124: 1013-1015.
2. Aksoy E, Goldman M, Willems F, (2004). Protein kinase C epsilon: a new target to control inflammation and immune-mediated disorders. Int J Biochem Cell Biol 36: 183-188.
3. Alawi K, Keeble J, (2010). The paradoxical role of the transient receptor potential vanilloid 1 receptor in inflammation. Pharmacol Ther 125: 181-195.
4. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164: S1-S324.
5. Almeida MC, Steiner AA, Branco LG, Romanovsky AA, (2006). Cold-seeking behavior as a thermoregulatory strategy in systemic inflammation. Eur J Neurosci 23: 3359-3367.
6. Amadesi S, Nie J, Vergnolle N, Cottrell GS, Grady EF, Trevisani M, et al. (2004). Protease-activated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J Neurosci 24: 4300-4312.
7. 4 receptor on the dorsal root ganglion neurons in mice. Brain Res Mol Brain Res 137: 263-266.
8. Andoh T, Nagasawa T, Kuraishi Y, (1996). Expression of tachykinin NK1 receptor mRNA in dorsal root ganglia of the mouse. Brain Res Mol Brain Res 35: 329-332.
9. Ang SF, Moochhala SM, MacAry PA, Bhatia M, (2011). Hydrogen sulfide and neurogenic inflammation in polymicrobial sepsis: involvement of substance P and ERK-NF-κB signaling. PLoS ONE 6: e24535.
10. Ansari N, Khodagholi F, Amini M, Shaerzadeh F, (2011). Attenuation of LPS-induced apoptosis in NGF-differentiated PC12 cells via NF-κB pathway and regulation of cellular redox status by an oxazine derivative. Biochimie 93: 899-908.
11. Asmis LM, Asmis R, Sulzer I, Furlan M, Lämmle B, (2008). Contact system activation in human sepsis-47kD HK, a marker of sepsis severity? Swiss Med Wkly 138: 142-149.
12. Ayala A, Chaudry IH, (1996). Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock 6: S27-S38.
13. Baranauskas G, Nistri A, (1998). Sensitization of pain pathways in the spinal cord: cellular mechanisms. Prog Neurobiol 54: 349-365.
14. Bátkai S, Pacher P, Járai Z, Wagner JA, Kunos G, (2004). Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am J Physiol Heart Circ Physiol 287: H595-H600.
15. Beer S, Weighardt H, Emmanuilidis K, Harzenetter MD, Matevossian E, Heidecke CD, et al. (2002). Systemic neuropeptide levels as predictive indicators for lethal outcome in patients with postoperative sepsis. Crit Care Med 30: 1794-1798.
16. Beny JL, Brunet PC, Huggel H, (1986). Effect of mechanical stimulation, substance P and vasoactive intestinal polypeptide on the electrical and mechanical activities of circular smooth muscles from pig coronary arteries contracted with acetylcholine: role of endothelium. Pharmacology 33: 61-68.
17. Berg RM, Møller K, Bailey DM, (2011). Neuro-oxidative-nitrosative stress in sepsis. J Cereb Blood Flow Metab 31: 1532-1544.
18. Bhatia M, Slavin J, Cao Y, Basbaum AI, Neoptolemos JP, (2003). Preprotachykinin-A gene deletion protects mice against acute pancreatitis and associated lung injury. Am J Physiol Gastrointest Liver Physiol 284: G830-G836.
19. Bodkin JV, Brain SD, (2011). Transient receptor potential ankyrin 1: emerging pharmacology and indications for cardiovascular biology. Acta Physiol 203: 87-98.
20. Brain SD, Cox HM, (2006). Neuropeptides and their receptors: innovative science providing novel therapeutic targets. Br J Pharmacol 147: S202-S211.
21. Bryant P, Shumate M, Yumet G, Lang CH, Vary TC, Cooney RN, (2003). Capsaicin-sensitive nerves regulate the metabolic response to abdominal sepsis. J Surg Res 112: 152-161.
22. Bury RW, Mashford ML, (1977). A pharmacological investigation of synthetic substance P on the isolated guinea-pig ileum. Clin Exp Pharmacol Physiol 4: 453-461.
23. Cantalupo L, Cioni C, Annunziata P, (2008). Expression of preprotachykinin-A mRNA isoforms and substance P production in T lymphocytes of human healthy subjects. Neurosci Lett 434: 191-194.
24. Cao YQ, Mantyh PW, Carlson EJ, Gillespie AM, Epstein CJ, Basbaum AI, (1998). Primary afferent tachykinins are required to experience moderate to intense pain. Nature 392: 390-394.
25. Caroleo MC, Costa N, Bracci-Laudiero L, Aloe L, (2001). Human monocyte/macrophages activate by exposure to LPS overexpress NGF and NGF receptors. J Neuroimmunol 113: 193-201.
26. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D, (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389: 816-824.
27. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, et al. (2000). Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288: 306-313.
28. Chen CW, Lee ST, Wu WT, Fu WM, Ho FM, Lin WW, (2003). Signal transduction for inhibition of inducible nitric oxide synthase and cyclooxygenase-2 induction by capsaicin and related analogs in macrophages. Br J Pharmacol 140: 1077-1087.
29. Cheyuo C, Jacob A, Wang P, (2012). Ghrelin-mediated sympathoinhibition and suppression of inflammation in sepsis. Am J Physiol Endocrinol Metab 302: E265-E272.
30. Ching LC, Kou YR, Shyue SK, Su KH, Wei J, Cheng LC, et al. (2011). Molecular mechanisms of activation of endothelial nitric oxide synthase mediated by transient receptor potential vanilloid type 1. Cardiovasc Res 91: 492-501.
31. Chuang HH, Prescott ED, Kong H, Shields S, Jordt SE, Basbaum AI, et al. (2001). Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 411: 957-962.
32. Clark N, Keeble J, Fernandes ES, Starr A, Liang L, Sugden D, et al. (2007). The transient receptor potential vanilloid 1 (TRPV1) receptor protects against the onset of sepsis after endotoxin. FASEB J 13: 3747-3755.
33. Coelho FR, Martins JO, (2012). Diagnostic methods in sepsis: the need of speed. Rev Assoc Med Bras 58: 498-504.
34. Croci T, Emonds-Alt X, Le Fur G, Manara L, (1995). In vitro characterization of the non-peptide tachykinin NK1 and NK2-receptor antagonists, SR140333 and SR48968 in different rat and guinea-pig intestinal segments. Life Sci 56: 267-275.
35. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, et al. (2000). Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405: 183-187.
36. De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJ, et al. (1998). Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 392: 394-397.
37. De Swert KO, Bracke KR, Demoor T, Brusselle GG, Joos GF, (2009). Role of the tachykinin NK1 receptor in a murine model of cigarette smoke-induced pulmonary inflammation. Respir Res 10: 37.
38. De Winter BY, De Man JG, (2010). Interplay between inflammation, immune system and neuronal pathways: effect on gastrointestinal motility. World J Gastroenterol 16: 5523-5535.
39. Delescluse I, Mace H, Adcock J, (2012). Inhibition of airway hyperresponsiveness by Trpv1 antagonists (SB705498 and PF-04065463) in the unanaesthetised, ovalbumin-sensitised guinea-pig. Br J Pharmacol 166: 1822-1832.
40. Dinh QT, Groneberg DA, Peiser C, Mingomataj E, Joachim RA, Witt C, et al. (2004). Substance P expression in TRPV1 and trkA-positive dorsal root ganglion neurons innervating the mouse lung. Respir Physiol Neurobiol 144: 15-24.
41. Diogenes A, Ferraz CC, Akopian AN, Henry MA, Hargreaves KM, (2011). LPS sensitizes TRPV1 via activation of TLR4 in trigeminal sensory neurons. J Dent Res 90: 759-764.
42. Duffy RA, (2004). Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs 1: 9-21.
43. Durrenberger PF, Facer P, Casula MA, Yiangou Y, Gray RA, Chessell IP, et al. (2006). Prostanoid receptor EP1 and Cox-2 in injured human nerves and a rat model of nerve injury: a time-course study. BMC Neurol 6: 1.
44. Espiritu RF, Pittet JF, Matthay MA, Goetzl EJ, (1992). Neuropeptides in pulmonary edema fluid of adult respiratory distress syndrome. Inflammation 16: 509-517.
45. Fehér E, Fodor M, Fehér J, (1992). Ultrastructural localization of somatostatin- and substance P-immunoreactive nerve fibers in the feline liver. Gastroenterology 102: 287-294.
46. Fernandes ES, Schmidhuber SM, Brain SD, (2009). Sensory-nerve-derived neuropeptides: possible therapeutic targets. Handb Exp Pharmacol 194: 393-416.
47. Fernandes ES, Fernandes MA, Keeble JE, (2012a). The functions of TRPA1 and TRPV1: moving away from sensory nerves. Br J Pharmacol 166: 510-521.
48. Fernandes ES, Liang L, Smillie SJ, Kaiser F, Purcell R, Rivett DW, et al. (2012b). TRPV1 deletion enhances local inflammation and accelerates the onset of systemic inflammatory response syndrome. J Immunol 188: 5741-5751.
49. Foreman JC, Jordan CC, Oehme P, Renner H, (1983). Structure-activity relationships for some substance P-related peptides that cause wheal and flare reactions in human skin. J Physiol 335: 449-465.
50. Gallicchio M, Benetti E, Rosa AC, Fantozzi R, (2009). Tachykinin receptor modulation of cyclooxygenase-2 expression in human polymorphonuclear leucocytes. Br J Pharmacol 156: 486-496.
51. Gavva NR, (2008). Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends Pharmacol Sci 29: 550-557.
52. Gavva NR, Klionsky L, Qu Y, Shi L, Tamir R, Edenson S, et al. (2004). Molecular determinants of vanilloid sensitivity in TRPV1. J Biol Chem 279: 20283-20295.
53. Gavva NR, Tamir R, Qu Y, Klionsky L, Zhang TJ, Immke D, et al. (2005). AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 313: 474-484.
54. Giamarellos-Bourboulis EJ, Raftogiannis M, (2012). The immune response to severe bacterial infections: consequences for therapy. Expert Rev Anti Infect Ther 10: 369-380.
55. Glaser S, Gaudio E, Renzi A, Mancinelli R, Ueno Y, Venter J, et al. (2011). Knockout of the neurokinin-1 receptor reduces cholangiocyte proliferation in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol 301: G297-G305.
56. Groneberg DA, Quarcoo D, Frossard N, Fischer A, (2004). Neurogenic mechanisms in bronchial inflammatory diseases. Allergy 59: 1139-1152.
57. Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM, et al. (2004). Identification and characterisation of SB366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology 46: 133-149.
58. Guptill V, Cui X, Khaibullina A, Keller JM, Spornick N, Mannes A, et al,. (2011). Disruption of the transient receptor potential vanilloid 1 can affect survival, bacterial clearance, and cytokine gene expression during murine sepsis. Anesthesiology 114: 1190-1199.
59. Hayes P, Meadows HJ, Gunthorpe MJ, Harries MH, Duckworth DM, Cairns W, et al. (2000). Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Pain 88: 205-215.
60. Hegde A, Zhang H, Moochhala SM, Bhatia M, (2007). Neurokinin-1 receptor antagonist treatment protects mice against lung injury in polymicrobial sepsis. J Leukoc Biol 82: 678-685.
61. Hegde A, Tamizhselvi R, Manikandan J, Melendez AJ, Moochhala SM, Bhatia M, (2010a). Substance P in polymicrobial sepsis: molecular fingerprint of lung injury in preprotachykinin-A-/- mice. Mol Med 16: 188-198.
62. Hegde A, Koh YH, Moochhala SM, Bhatia M, (2010b). Neurokinin-1 receptor antagonist treatment in polymicrobial sepsis: molecular insights. Int J Inflam 2010: 601098.
63. Helyes Z, Elekes K, Sándor K, Szitter I, Kereskai L, Pintér E, et al. (2010). Involvement of preprotachykinin A gene-encoded peptides and the neurokinin 1 receptor in endotoxin-induced murine airway inflammation. Neuropeptides 44: 399-406.
64. Henricks PA, Verhoef J, Nijkamp FP, (1986). Modulation of phagocytic cell function. Vet Res Commun 10: 165-188.
65. Hernández-Palazõn J, Fuentes-García D, Burguillos-Lõpez S, Domenech-Asensi P, Sansano-Sánchez TV, Acosta-Villegas F, (2012). Analysis of organ failure and mortality in sepsis due to secondary peritonitis. Med Intensiva doi:pii: S0210-5691(12)00250-1. 10.1016/j.medin.2012.07.010
66. Ho KW, Ward NJ, Calkins DJ, (2012). TRPV1: a stress response protein in the central nervous system. Am J Neurodegener Dis 30: 1-14.
67. Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD, (1997). Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol 59: 5654-5660.
68. Hökfelt T, Pernow B, Wahren J, (2001). Substance P: a pioneer amongst neuropeptides. J Intern Med 249: 27-40.
69. Holzer P, (1998). Neurogenic vasodilatation and plasma leakage in the skin. Gen Pharmacol 30: 5-11.
70. Holzer P, Holzer-Petsche U, (1997). Tachykinins in the gut. Part I. Expression, release and motor function. Pharmacol Ther 73: 173-217.
71. Hong S, Wiley JW, (2005). Early painful diabetic neuropathy is associated with differential changes in the expression and function of vanilloid receptor 1. J Biol Chem 280: 618-627.
72. Huang J, Zhang X, McNaughton PA, (2006a). Inflammatory pain: the cellular basis of heat hyperalgesia. Curr Neuropharmacol 4: 197-206.
73. Huang J, Zhang X, McNaughton PA, (2006b). Modulation of temperature-sensitive TRP channels. Semin Cell Dev Biol 17: 638-645.
74. Huang SC, Korlipara VL, (2010). Neurokinin-1 receptor antagonists: a comprehensive patent survey. Expert Opin Ther Pat 20: 1019-1045.
75. Huang W, Rubinstein J, Prieto AR, Thang LV, Wang DH, (2009). Transient receptor potential vanilloid gene deletion exacerbates inflammation and atypical cardiac remodeling after myocardial infarction. Hypertension 53: 243-250.
76. Hui Y, Du J, Tang C, Bin G, Jiang H, (2003). Changes in arterial hydrogen sulfide (H(2)S) content during septic shock and endotoxin shock in rats. J Infect 47: 155-160.
77. Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, (2000). Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A 97: 6155-6160.
78. Iida T, Shimizu I, Nealen ML, Campbell A, Caterina M, (2005). Attenuated fever response in mice lacking TRPV1. Neurosci Lett 378: 28-33.
79. Improta G, Broccardo M, (2006). Tachykinins: role in human gastrointestinal tract physiology and pathology. Curr Drug Targets 7: 1021-1029.
80. Jacob P, Mueller MH, Hahn J, Wolk I, Mayer P, Nagele U, et al. (2007). Alterations of neuropeptides in the human gut during peritonitis. Langenbecks Arch Surg 392: 267-271.
81. Jang JH, Clark JD, Li X, Yorek MS, Usachev YM, Brennan TJ, (2010). Nociceptive sensitization by complement C5a and C3a in mouse. Pain 148: 343-352.
82. Jia Y, Lee LY, (2007). Role of TRPV receptors in respiratory diseases. Biochim Biophys Acta 1772: 915-927.
83. Joachim RA, Cifuentes LB, Sagach V, Quarcoo D, Hagen E, Arck PC, Fischer A, Klapp BF, Dinh QT, (2006). Stress induces substance P in vagal sensory neurons innervating the mouse airways. Clin Exp Allergy 36: 1001-1010.
84. Kadoi Y, Hinohara H, Kunimoto F, Kuwano H, Saito S, Goto F, (2005). Effects of AM281, a cannabinoid antagonist, on systemic haemodynamics, internal carotid artery blood flow and mortality in septic shock in rats. Br J Anaesth 94: 563-568.
85. Kark T, Bagi Z, Lizanecz E, Pásztor ET, Erdei N, Czikora A, (2008). Tissue-specific regulation of microvascular diameter: opposite functional roles of neuronal and smooth muscle located vanilloid receptor-1. Mol Pharmacol 73: 1405-1412.
86. Katsanos GS, Anogeianaki A, Orso C, Tete S, Salini V, Antinolfi PL, (2008). Impact of substance P on cellular immunity. J Biol Regul Homeost Agents 22: 93-98.
87. Katz LM, Marr CM, Elliott J, (2003). Characterisation of the response of equine digital arteries and veins to substance P. J Vet Pharmacol Ther 26: 361-368.
88. Kazerani HR, Plevin R, Kawagoe J, Kanke T, Furman BL, (2004). Lack of effect of proteinase-activated receptor-2 (PAR-2) deletion on the pathophysiological changes produced by lipopolysaccharide in the mouse: comparison with dexamethasone. J Pharm Pharmacol 56: 1015-1020.
89. Keeble JE, Brain SD, (2004). A role for substance P in arthritis? Neurosci Lett 361: 176-179.
90. Keeble JE, Bodkin JV, Liang L, Wodarski R, Davies M, Fernandes ES, et al. (2009). Hydrogen peroxide is a novel mediator of inflammatory hyperalgesia, acting via transient receptor potential vanilloid 1-dependent and independent mechanisms. Pain 141: 135-142.
91. Kitamura H, Kobayashi M, Wakita D, Nishimura T, (2012). Neuropeptide signaling activates dendritic cell-mediated type 1 immune responses through neurokinin-2 receptor. J Immunol 188: 4200-4208.
92. Konno M, Shirakawa H, Iida S, Sakimoto S, Matsutani I, Miyake T, et al. (2012). Stimulation of transient receptor potential vanilloid 4 channel suppresses abnormal activation of microglia induced by lipopolysaccharide. Glia 60: 761-770.
93. Kuzhikandathil EV, Wang H, Szabo T, Morozova N, Blumberg P, Oxford GS, (2001). Functional analysis of capsaicin receptor (vanilloid receptor subtype 1) multimerization and agonist responsiveness using a dominant negative mutation. J Neurosci 21: 8697-8706.
94. Lai JP, Douglas SD, Ho WZ, (1998). Human lymphocytes express substance P and its receptor. J Neuroimmunol 86: 80-86.
95. Laird JM, Olivar T, Roza C, De Felipe C, Hunt SP, Cervero F, (2000). Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK1 receptor gene. Neuroscience 98: 345-352.
96. Laird JM, Roza C, De Felipe C, Hunt SP, Cervero F, (2001). Role of central and peripheral tachykinin NK1 receptors in capsaicin-induced pain and hyperalgesia in mice. Pain 90: 97-103.
97. Lautner MA, Ruparel SB, Patil MJ, Hargreaves KM, (2011). In vitro sarcoma cells release a lipophilic substance that activates the pain transduction system via TRPV1. Ann Surg Oncol 18: 866-871.
98. Lever A, Mackenzie I, (2007). Sepsis: definition, epidemiology, and diagnosis. BMJ 335: 879-883.
99. Li J, Wang DH, (2008). Increased GFR and renal excretory function by activation of TRPV1 in the isolated perfused kidney. Pharmacol Res 57: 239-246.
100. Li L, Bhatia M, Zhu YZ, Zhu YC, Ramnath RD, Wang ZJ, et al. (2005). Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. FASEB J 19: 1196-1198.
101. Li L, Hsu A, Moore PK, (2009). Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation-a tale of three gases! Pharmacol Ther 123: 386-400.
102. Lichtenstern C, Brenner T, Bardenheuer HJ, Weigand MA, Lin Q, (2012). Predictors of survival in sepsis: what is the best inflammatory marker to measure? Curr Opin Infect Dis 25: 328-336.
103. Lin Q, Li D, Xu X, Zou X, Fang L, (2007). Roles of TRPV1 and neuropeptidergic receptors in dorsal root reflex-mediated neurogenic inflammation induced by intradermal injection of capsaicin. Mol Pain 3: 30.
104. Lotz M, Vaughan JH, Carson DA, (1988). Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 241: 1218-1221.
105. Maggi CA, (1997). The effects of tachykinins on inflammatory and immune cells. Regul Pept 70: 75-90.
106. Margolis KG, Gershon MD, (2009). Neuropeptides and inflammatory bowel disease. Curr Opin Gastroenterol 25: 503-511.
107. Matsumoto K, Hosoya T, Tashima K, Namiki T, Murayama T, Horie S, (2011). Distribution of transient receptor potential vanilloid 1 channel-expressing nerve fibers in mouse rectal and colonic enteric nervous system: relationship to peptidergic and nitrergic neurons. Neuroscience 172: 518-534.
108. Mayer AM, (1998). Therapeutic implications of microglia activation by lipopolysaccharide and reactive oxygen species generation in septic shock and central nervous system pathologies: a review. Medicina (B Aires) 58: 377-385.
109. Mechiche H, Koroglu A, Candenas L, Pinto FM, Birembaut P, Bardou M, et al. (2003). Neurokinins induce relaxation of human pulmonary vessels through stimulation of endothelial NK1 receptors. J Cardiovasc Pharmacol 41: 343-355.
110. Mezey E, Tõth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, et al. (2000). Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A 97: 3655-3660.
111. Miao X, Liu G, Xu X, Xie C, Sun F, Yang Y, et al. (2008). High expression of vanilloid receptor-1 is associated with better prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 186: 25-32.
112. Murai M, Morimoto H, Maeda Y, Fujii T, (1992). Effects of the tripeptide substance P antagonist, FR113680, on airway constriction and airway edema induced by neurokinins in guinea-pigs. Eur J Pharmacol 217: 23-29.
113. Nakagawa N, Sano H, Iwamoto I, (1995). Substance P induces the expression of intercellular adhesion molecule-1 on vascular endothelial cells and enhances neutrophil transendothelial migration. Peptides 16: 721-725.
114. Neunaber C, Zeckey C, Andruszkow H, Frink M, Mommsen P, Krettek C, et al. (2011). Immunomodulation in polytrauma and polymicrobial sepsis-where do we stand? Recent Pat Inflamm Allergy Drug Discov 5: 17-25.
115. Ng SW, Zhang H, Hegde A, Bhatia M, (2008). Role of preprotachykinin-A gene products on multiple organ injury in LPS- induced endotoxemia. J Leukoc Biol 83: 288-295.
116. 2-loaded microspheres as strategy to inhibit phagocytosis and modulate inflammatory mediators release. Eur J Pharm Biopharm 70: 784-790.
117. Noga O, Peiser M, Altenähr M, Schmeck B, Wanner R, Dinh QT, et al. (2008). Selective induction of nerve growth factor and brain-derived neurotrophic factor by LPS and allergen in dendritic cells. Clin Exp Allergy 38: 473-479.
118. O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F, (2004). The role of substance P in inflammatory disease. J Cell Physiol 201: 167-180.
119. Ochoa-Cortes F, Ramos-Lomas T, Miranda-Morales M, Spreadbury I, Ibeakanma C, Barajas-Lopez C, et al. (2010). Bacterial cell products signal to mouse colonic nociceptive dorsal root ganglia neurons. Am J Physiol Gastrointest Liver Physiol 299: G723-G732.
120. Okada T, Hirayama Y, Kishi S, Miyayasu K, Hiroi J, Fujii T, (1999). Functional neurokinin NK-1 receptor expression in rat peritoneal mast cells. Inflamm Res 48: 274-279.
121. Orsal AS, Blois S, Labuz D, Peters EM, Schaefer M, Arck PC, (2006). The progesterone derivative dydrogesterone down-regulates neurokinin 1 receptor expression on lymphocytes, induces a Th2 skew and exerts hypoalgesic effects in mice. J Mol Med 84: 159-167.
122. Pan XQ, Gonzalez JA, Chang S, Chacko S, Wein AJ, Malykhina AP, (2010). Experimental colitis triggers the release of substance P and calcitonin gene-related peptide in the urinary bladder via TRPV1 signaling pathways. Exp Neurol 225: 262-273.
123. Patacchini R, Santicioli P, Giuliani S, Maggi CA, (2004). Hydrogen sulfide (H2S) stimulates capsaicin-sensitive primary afferent neurons in the rat urinary bladder. Br J Pharmacol 142: 31-34.
124. Patacchini R, Santicioli P, Giuliani S, Maggi CA, (2005). Pharmacological investigation of hydrogen sulfide (H2S) contractile activity in rat detrusor muscle. Eur J Pharmacol 509: 171-177.
125. Patel L, Lindley C, (2003). Aprepitant-a novel NK1-receptor antagonist. Expert Opin Pharmacother 4: 2279-2296.
126. Pawlinski R, Mackman N, (2004). Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Crit Care Med 32: S293-S297.
127. Pedersen SF, Owsianik G, Nilius B, (2005). TRP channels: an overview. Cell Calcium 38: 233-252.
128. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, Maggi CA, (2004). Tachykinins and tachykinin receptors: a growing family. Life Sci 74: 1445-1463.
129. Pernow B, (1953). Distribution of substance P in the central and peripheral nervous system. Nature 171: 746.
130. Premkumar LS, Abooj M, (2012). TRP channels and analgesia. Life Sci dx.doi.org/ 10.10016/j.lfs.2012.08.010.
131. Puneet P, Hegde A, Ng SW, Lau HY, Lu J, Moochhala SM, et al. (2006). Preprotachykinin-A gene products are key mediators of lung injury in polymicrobial sepsis. J Immunol 176: 3813-3820.
132. Puntambekar P, Mukherjea D, Jajoo S, Ramkumar V, (2005). Essential role of Rac1/NADPH oxidase in nerve growth factor induction of TRPV1 expression. J Neurochem 95: 1689-1703.
133. Quartara L, Maggi CA, (1997). The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides 31: 537-563.
134. Rios-Santos F, Benjamim CF, Zavery D, Ferreira SH, Cunha FdeQ, (2003). A critical role of leukotriene B4 in neutrophil migration to infectious focus in cecal ligaton and puncture sepsis. Shock 19: 61-65.
135. Ro JY, Lee JS, Zhang Y, (2009). Activation of TRPV1 and TRPA1 leads to muscle nociception and mechanical hyperalgesia. Pain 144: 270-277.
136. Rogers DP, Wyatt CR, Walz PH, Drouillard JS, Mosier DA, (2006). Bovine alveolar macrophage neurokinin-1 and response to substance P. Vet Immunol Immunopathol 112: 290-295.
137. Romanovsky AA, (2004). Signaling the brain in the early sickness syndrome: are sensory nerves involved? Front Biosci 9: 494-504.
138. Russell FA, Fernandes ES, Courade JP, Keeble JE, Brain SD, (2009). Tumour necrosis factor alpha mediates transient receptor potential vanilloid 1-dependent bilateral thermal hyperalgesia with distinct peripheral roles of interleukin-1beta, protein kinase C and cyclooxygenase-2 signalling. Pain 142: 264-274.
139. Rychkov GY, Barritt GJ, (2011). Expression and function of TRP channels in liver cells. Adv Exp Med Biol 704: 667-686.
140. Samways DS, Egan TM, (2011). Calcium-dependent decrease in the single-channel conductance of TRPV1. Pflugers Arch 462: 681-691.
141. Sann H, Pierau FK, (1998). Efferent functions of C-fiber nociceptors. Z Rheumatol 57: 8-13.
142. Saunders CI, Kunde DA, Crawford A, Geraghty DP, (2007). Expression of transient receptor potential vanilloid 1 (TRPV1) and 2 (TRPV2) in human peripheral blood. Mol Immunol 44: 1429-1435.
143. Sawyer I, Smillie SJ, Bodkin JV, Fernandes E, O'Byrne KT, Brain SD, (2011). The vasoactive potential of kisspeptin-10 in the peripheral vasculature. PLoS ONE 26: e14671.
144. Schnizler K, Shutov LP, Van Kanegan MJ, Merrill MA, Nichols B, McKnight GS, et al. (2008). Protein kinase A anchoring via AKAP150 is essential for TRPV1 modulation by forskolin and prostaglandin E2 in mouse sensory neurons. J Neurosci 28: 4904-4917.
145. Scotland RS, Chauhan S, Davis C, De Felipe C, Hunt S, Kabir J, et al. (2004). Vanilloid receptor TRPV1, sensory C-fibers, and vascular autoregulation: a novel mechanism involved in myogenic constriction. Circ Res 95: 1027-1034.
146. Shimaoka M, Park EJ, (2008). Advances in understanding sepsis. Eur J Anaesthesiol 42: 146-153.
147. Sipka A, Langner K, Seyfert HM, Schuberth HJ, (2010). Substance P alters the in vitro LPS responsiveness of bovine monocytes and blood-derived macrophages. Vet Immunol Immunopathol 136: 219-226.
148. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, et al. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129: 227-230.
149. Snider RM, Constantine JW, Lowe JA 3rd, Longo KP, Lebel WS, Woody HA, et al. (1991). A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 251: 435-437.
150. Starr A, Graepel R, Keeble J, Schmidhuber S, Clark N, Grant A, et al,. (2008). A reactive oxygen species-mediated component in neurogenic vasodilatation. Cardiovasc Res 78: 139-147.
151. Sun J, Ramnath RD, Bhatia M, (2007). Neuropeptide substance P upregulates chemokine and chemokine receptor expression in primary mouse neutrophils. Am J Physiol Cell Physiol 293: C696-C704.
152. Szolcsányi J, Jancsõ-Gábor A, (1975). Sensory effects of capsaicin congeners I. Relationship between chemical structure and pain-producing potency of pungent agents. Arzneimittelforschung 25: 1877-1881.
153. Tamizhselvi R, Shrivastava P, Koh YH, Zhang H, Bhatia M, (2011). Preprotachykinin-A gene deletion regulates hydrogen sulfide-induced toll-like receptor 4 signalling pathway in cerulein-treated pancreatic acinar cells. Pancreas 40: 444-452.
154. Tékus V, Bölcskei K, Kis-Varga A, Dézsi L, Szentirmay E, Visegrády A, et al. (2010). Effect of transient receptor potential vanilloid 1 (TRPV1) receptor antagonist compounds SB705498, BCTC and AMG9810 in rat models of thermal hyperalgesia measured with an increasing-temperature water bath. Eur J Pharmacol 641: 135-141.
155. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, et al. (1998). The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21: 531-543.
156. Trevisani M, Patacchini R, Nicoletti P, Gatti R, Gazzieri D, Lissi N, et al. (2005). Hydrogen sulfide causes vanilloid receptor 1-mediated neurogenic inflammation in the airways. Br J Pharmacol 145: 1123-1131.
157. Tuncer LI, Alaçam T, Oral B, (2004). Substance P expression is elevated in inflamed human periradicular tissue. J Endod 30: 329-332.
158. Ufret-Vincenty CA, Klein RM, Hua L, Angueyra J, Gordon SE, (2011). Localization of the PIP2 sensor of TRPV1 ion channels. J Biol Chem 286: 9688-9698.
159. Varga K, Wagner JA, Bridgen DT, Kunos G, (1998). Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12: 1035-1044.
160. Vercelli CA, Aisemberg J, Billi S, Cervini M, Ribeiro ML, Farina M, et al. (2009). Anandamide regulates lipopolysaccharide-induced nitric oxide synthesis and tissue damage in the murine uterus. Reprod Biomed Online 18: 824-831.
161. Voight EA, Kort ME, (2010). Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature. Expert Opin Ther Pat 20: 1107-1122.
162. Von Euler US, Gaddum JH, (1931). An unidentified depressor substance in certain tissue extracts. J Physiol 72: 74-87.
163. Wadachi R, Hargreaves KM, (2006). Trigeminal nociceptors express TLR-4 and CD14: a mechanism for pain due to infection. J Dent Res 85: 49-53.
164. Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ, et al. (2003). The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 304: 56-62.
165. Wall PD, (1982). The effect of peripheral nerve lesions and of neonatal capsaicin in the rat on primary afferent depolarization. J Physiol 329: 21-35.
166. Wanner SP, Garami A, Pakai E, Oliveira DL, Gavva NR, Coimbra CC, et al. (2012). Aging reverses the role of the transient receptor potential vanilloid-1 channel in systemic inflammation from anti-inflammatory to proinflammatory. Cell Cycle 11: 343-349.
167. Westphal M, Sander J, Van Aken H, Ertmer C, Stubbe HD, Booke M, (2006). Role of adrenomedullin in the pathogenesis and treatment of cardiovascular dysfunctions and sepsis. Anaesthesist 55: 171-178.
168. Yang D, Luo Z, Ma S, Wong WT, Ma L, Zhong J, et al. (2010). Activation of TRPV1 by dietary capsaicin improves endothelium-dependent vasorelaxation and prevents hypertension. Cell Metab 12: 130-141.
169. Zhang H, Zhi L, Moochhala S, Moore PK, Bhatia M, (2007a). Hydrogen sulfide acts as an inflammatory mediator in cecal ligation and puncture-induced sepsis in mice by upregulating the production of cytokines and chemokines via NF-kappaB. Am J Physiol Lung Cell Mol Physiol 292: L960-L971.
170. Zhang H, Hegde A, Ng SW, Adhikari S, Moochhala SM, Bhatia M, (2007b). Hydrogen sulfide up-regulates substance P in polymicrobial sepsis-associated lung injury. J Immunol 179: 4153-4160.
171. Zhang L, Jones S, Brody K, Costa M, Brookes SJ, (2004). Thermosensitive transient receptor potential channels in vagal afferent neurons of the mouse. Am J Physiol Gastrointest Liver Physiol 286: G983-G991.
172. Zhang X, Li L, McNaughton PA, (2008). Proinflammatory mediators modulate the heat-activated ion channel TRPV1 via the scaffolding protein AKAP79/150. Neuron 59: 450-461.
173. Zimmer A, Zimmer AM, Baffi J, Usdin T, Reynolds K, König M, et al. (1998). Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. Proc Natl Acad Sci U S A 95: 2630-2635.
174. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sørgård M, Di Marzo V, et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400: 452-457.